Spyre Therapeutics (SYRE) Other Non-Current Assets (2015 - 2025)
Spyre Therapeutics (SYRE) posted Other Non-Current Assets of $10000.0 for Q1 2025, little changed on a QoQ basis from $10000.0 in Q4 2024, and little changed year-over-year from $10000.0 in Q1 2024.
Spyre Therapeutics (SYRE) Other Non-Current Assets (2015 - 2025) Analysis & Trends
Spyre Therapeutics' Other Non-Current Assets history runs 11 years deep, the most recent figure standing at $10000.0 for Q1 2025.
- Quarterly Other Non-Current Assets changed 0.0% year-over-year to $10000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $10000.0 (changed 0.0% YoY) and the FY2024 annual result came in at $10000.0, up 11.11% from the prior year.
- Other Non-Current Assets was $10000.0 for Q1 2025 at Spyre Therapeutics, roughly flat from $10000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.8 million in Q2 2021 and bottomed at $9000.0 in Q4 2023.
- A 5-year average of $904562.5 and a median of $824500.0 in 2021 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2021 — Other Non-Current Assets surged 1906.52% — and 2023, when it sank 99.42%.
- Spyre Therapeutics' Other Non-Current Assets stood at $1.8 million in 2021, then retreated by 15.51% to $1.6 million in 2022, then sank by 99.42% to $9000.0 in 2023, then advanced by 11.11% to $10000.0 in 2024, then changed by 0.0% to $10000.0 in 2025.
- Business Quant data shows SYRE's Other Non-Current Assets at $10000.0 in Q1 2025, $10000.0 in Q4 2024, and $321000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,946.26 Bn | 1,946.20 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | 60,000.00 |
| 4 | BeOne Medicines | 473.25 Bn | 468.46 Bn | 1.35 Bn | 104.24 Mn |
| 5 | Vertex Pharmaceuticals | 123.17 Bn | 115.92 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 69.54 Bn | 60.79 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 63.20 Bn | 63.20 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 56.91 Bn | 51.72 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 38.23 Bn | 38.23 Bn | - | 14.48 Mn |
| 10 | Spyre Therapeutics | 267.35 Mn | 267.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | 10,000.00 |
| Jun 30, 2024 | 321,000.00 |
| Mar 31, 2024 | 10,000.00 |
| Dec 31, 2023 | 9,000.00 |
| Sep 30, 2023 | 1.31 Mn |
| Jun 30, 2023 | 1.32 Mn |
| Mar 31, 2023 | 1.31 Mn |
| Dec 31, 2022 | 1.55 Mn |
| Sep 30, 2022 | 749,000.00 |
| Jun 30, 2022 | 752,000.00 |
| Mar 31, 2022 | 1.83 Mn |
| Dec 31, 2021 | 1.84 Mn |
| Sep 30, 2021 | 897,000.00 |
| Jun 30, 2021 | 1.85 Mn |
| Mar 31, 2021 | 716,000.00 |
| Dec 31, 2020 | 115,000.00 |
| Sep 30, 2020 | 122,000.00 |
| Jun 30, 2020 | 92,000.00 |
| Mar 31, 2020 | 1.50 Mn |